CHU Dijon Bourgogne
Dijon, 21079, France
NCT Number: NCT03317093
Ceftobiprole is a very active new cephalosporin on staphylococci resistant to methicillin (SEMR: Staphylococcus epidermidis Resistant to Meticillin, SAMR: Staphylococcus aureus Resistant to Meticillin) and / or vancomycin; it is also very active on pneumococci resistant to penicillin and / or 3rd generation cephalosporins. This new drug has AMM in nosocomial respiratory infections, Animal work shows the efficacy of ceftobiprole in gram negative bacillus meningeal infections.
The rationale of this study is based on the antibacterial spectrum of ceftobiprole, which would therefore be useful in the treatment of staphylococcal bacterial meningitis resistant patients (SEMR or SAMR) encountered in intensive care and / or neurosurgery and in the treatment of pneumococcal meningitis.
To validate these possibilities, it is necessary to know the concentrations of ceftobiprole in the meningeal space.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Dijon, 21079, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
Time frame: Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours
Time frame: Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours
Centre Hospitalier Universitaire Dijon
Other
Acronym: BASILE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02806882
Meningitis, Nervous System Diseases
Dijon, France
View Trial DetailsNCT06649097
Brain Diseases, Cardiovascular Diseases
New York, United States
View Trial DetailsNCT05649904
Brain Diseases, Cardiovascular Diseases
Columbus, Ohio, United States
View Trial Details